Ovalbumin (OVA)-Induced Asthma Model

Creative Bioarray offers stable ovalbumin (OVA)-induced asthma model to help our clients evaluate the efficacy of their test compounds. Our model is designed to provide accurate and consistent results that can help you accelerate the development process of your compounds. With our services, you can gain valuable insights into the potential efficacy of your compound on asthma symptoms, allowing you to make informed decisions about how to proceed with your research.

OVA is the main protein found in egg white, which is not intrinsically immunogenic and therefore needs to be injected systemically in the presence of adjuvants, typically aluminum hydroxide (alum), to induce Th2 sensitization in mice. This animal model features many similarities to human allergic asthma, including the presence of eosinophilic lung inflammation, the release of inflammatory mediators and cytokines, and the presence of airway hyperresponsiveness after the antigen challenge. Researchers have extensively studied this model to understand the underlying mechanisms of allergic asthma and develop effective treatments.

Our Ovalbumin (OVA)-Induced Asthma Model

• Animal Available
  Mouse
• Modeling Method
  In the sensitization phase: mice are intraperitoneally injected with OVA complexed with aluminum.
  In the challenge phase: mice are challenged with OVA, resulting in many features of asthma.
• Endpoints
  • BALF analysis
  • Serum IgE level analysis: total IgE, OVA specific IgE
  • Cytokine analysis
  • Histology analysis: H&E staining (lung)
  • qPCR or Western Blot
  • Other customized endpoints: available upon request

Fig. 1 Workflow of our OVA-induced asthma model

Example Data

Fig. 2 The effects of Renifolin F on cytokine production in serum and BALF. (A) The levels of total IgE and allergen-specific IgE in serum. (B) The levels of IL-4, IL-5, IL-13, IL-9 and IL-6 in BALF. Normal control, saline-induced mice only. Model, OVA-induced mice. Dex, OVA-induced mice treated with Dex (1.0 mg/kg). RF-H, OVA-induced mice treated with Renifolin F (3.0 mg/kg). RF-L, OVA-induced mice treated with Renifolin F (1.5 mg/kg).

Fig. 3 The effects of Renifolin F on histopathologic changes in the lung tissues of OVA-induced allergic mice in vivo. (A) Lung tissue sections were stained with H&E. (B) Lung tissue sections were stained with PAS. Normal control, saline-induced mice only. Model, OVA-induced mice. Dex, OVA-induced mice treated with Dex (1.0 mg/kg). RF-H, OVA-induced mice treated with Renifolin F (3.0 mg/kg). RF-L, OVA-induced mice treated with Renifolin F (1.5 mg/kg).

Additionally, we also provide another asthma model that maybe you are interested in:

• House Dust Mite (HDM)-Induced Asthma Model

Quotation and Ordering

Creative Bioarray stands as a preeminent research partner, specializing in a diverse array of rodent disease models and offering an unparalleled breadth of related services. With our skilled scientists, we are committed to assisting you in selecting the most suitable model and crafting a meticulous study plan tailored to your specific needs. If you are interested in our services, please do not hesitate to contact us at any time or submit an inquiry to us directly.

Reference

1. Yang, Z., et al. Therapeutic effect of Renifolin F on airway allergy in an ovalbumin-induced asthma mouse model in vivo. Molecules, 2022, 27(12): 3789.

For research use only. Not for any other purpose.